Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Naltrexone and Acetaminophen for Episodic Migraine Prevention
NCT03194555Phase 2Completed
- Sponsor
- Allodynic Therapeutics
- Start
- Aug 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in episodic migraine comparing Low-Dose Naltrexone + Acetaminophen with Placebo (2 arms). Primary endpoint: Change in Monthly Migraine Days From Baseline to the Last 28 Days of Treatment Period at 12 weeks. Started Aug 2017; status: completed.
02
Drugs
naltrexoneacetaminophen
03
Conditions
episodic migraine
Beyond the preview
Go deeper on NCT03194555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03194555.